Toll Free: 1-888-928-9744

Anaplastic Thyroid Cancer - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anaplastic Thyroid Cancer - Pipeline Review, H1 2016

Summary
Global Markets Direct's, 'Anaplastic Thyroid Cancer - Pipeline Review, H1 2016', provides an overview of the Anaplastic Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Thyroid Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer - The report reviews pipeline therapeutics for Anaplastic Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Anaplastic Thyroid Cancer therapeutics and enlists all their major and minor projects - The report assesses Anaplastic Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Anaplastic Thyroid Cancer Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Anaplastic Thyroid Cancer Overview 7 Therapeutics Development 8 Pipeline Products for Anaplastic Thyroid Cancer - Overview 8 Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis 9 Anaplastic Thyroid Cancer - Therapeutics under Development by Companies 10 Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11 Anaplastic Thyroid Cancer - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Anaplastic Thyroid Cancer - Products under Development by Companies 14 Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes 15 Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development 16 Daiichi Sankyo Company, Limited 16 Exelixis, Inc. 17 Genelux Corporation 18 Immune Pharmaceuticals Inc. 19 Millennium Pharmaceuticals, Inc. 20 Novartis AG 21 Plexxikon Inc. 22 Anaplastic Thyroid Cancer - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Combination Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 cabozantinib s-malate - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ceritinib - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 CLM-3 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 CLM-94 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 crolibulin - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 efatutazone - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 GLONC-2 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 GLV-1h153 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 pexidartinib - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 PLX-8394 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 sapanisertib - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Anaplastic Thyroid Cancer - Recent Pipeline Updates 57 Anaplastic Thyroid Cancer - Dormant Projects 82 Anaplastic Thyroid Cancer - Product Development Milestones 83 Featured News & Press Releases 83 Apr 18, 2013: Combination Therapy Shows Promise against Anaplastic Thyroid Cancer, Study Finds 83 Appendix 84 Methodology 84 Coverage 84 Secondary Research 84 Primary Research 84 Expert Panel Validation 84 Contact Us 84 Disclaimer 85
List of Tables
Number of Products under Development for Anaplastic Thyroid Cancer, H1 2016 8 Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Anaplastic Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 16 Anaplastic Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2016 17 Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H1 2016 18 Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc., H1 2016 19 Anaplastic Thyroid Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 20 Anaplastic Thyroid Cancer - Pipeline by Novartis AG, H1 2016 21 Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Assessment by Combination Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Anaplastic Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2016 57 Anaplastic Thyroid Cancer - Dormant Projects, H1 2016 82



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify